Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
WuXi Biologics and its Chinese partner Harbin Gloria Pharmaceuticals Co. Ltd. (Gloria) granted an exclusive license for their Phase...